SQIN-Furosemide

Phase 2Small molecule

NNHS Greater Glasgow and Clyde

SQIN-Furosemide is one of 23 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Zemplar

AbbVie

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Coumadin

AAbbott

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

SQIN-Furosemide

NNHS Greater Glasgow and Clyde

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure1 trial

Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

Recruiting·NNHS Greater Glasgow and Clyde·Phase 2·NCT05419115·170 enrolled

Intravenous1 trial

Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

Completed·SSQ Innovation, Inc.·Phase 1·NCT07269496·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SQIN-Furosemide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SQIN-Furosemide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SQIN-Furosemide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NHS Greater Glasgow and Clyde company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNHS Greater Glasgow and Clyde

SQIN-Furosemide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News